Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    Soricimed
Previous Study | Return to List | Next Study

Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01578564
Recruitment Status : Completed
First Posted : April 17, 2012
Last Update Posted : June 23, 2016
Information provided by (Responsible Party):
Soricimed Biopharma Inc

Brief Summary:
The purpose of this study is to determine the safety and tolerability of the drug SOR-C13 when given as an intravenous infusion in patients with ovarian cancer or other cancers known to over express the TRPV6 calcium channel.

Condition or disease Intervention/treatment Phase
Cancer Drug: SOR-C13 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel
Study Start Date : July 2012
Actual Primary Completion Date : July 2015
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SOR-C13 Drug: SOR-C13
Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period

Primary Outcome Measures :
  1. Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Over 21 days from initial administration ]

Secondary Outcome Measures :
  1. Plasma levels of SOR-C13 [ Time Frame: Pre-treatment and up to 4 hours post-treatment on Study Days 1, 3, 8 and 10 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Males and females ≥ 18 years of age
  • Subjects with a histologic diagnosis of solid tumor cancers of epithelial origin.
  • Subjects with advanced refractory cancer for which standard curative or palliative measures do not exist or are no longer effective. There is no limitation on the number or types of prior therapy.
  • Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment.
  • ECOG (Eastern Cooperative Oncology Group) Performance Score ≤ 1.
  • Life expectancy of greater than 12 weeks.
  • Subjects must have adequate organ and marrow function as defined below:

    1. hemoglobin ≥9.0 g/dL (≥5.6 mmol/L)
    2. white blood cells ≥3,000/mm³(≥3×10⁹/L)
    3. absolute neutrophil count ≥1,500/mm³ (≥1.5×10⁹/L)
    4. platelets ≥100,000/μL (≥100×10⁹/L)
    5. total bilirubin ≤1.5× upper limit of normal(ULN)
    6. AST/ALT/AP ≤2.5× ULN (ALT/AST ≤5.0x ULN in case of documented liver metastases
    7. creatinine ≤1.5× ULN
    8. albumin ≥3.0 g/dL (≥30 g/L)
    9. INR ≤1.4
  • Ability to understand and voluntarily sign the informed consent document

Exclusion Criteria:

  • Chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy will not be allowed within either 30 days, or 5 half lives (whichever is longer) prior to study drug administration.
  • History or clinical evidence of central nervous system (CNS) tumor involvement (metastases) or other known clinically relevant CNS pathology (e.g., epilepsy, seizure, paresis, aphasia, cerebellar disease, severe brain injury, psychosis).
  • Concurrent malignancy other than the solid tumor under investigation, requiring active treatment.
  • History of clinically significant allergic reaction attributed to any injected compound.
  • History of any of the following cardiovascular events or conditions within the past 6 months prior to enrolment: myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, New York Heart Association Class ≥ II chronic heart failure, hypokalemia, significant arrhythmia*; QTc interval >430 msec or use of drugs that prolong the QT interval at screening; family history of long QT syndrome.(* Significant arrhythmias are defined as symptoms of syncope or severe palpitations (palpitations requiring referral to cardiac monitoring), or ECG findings of supraventricular tachycardia (including ventricular fibrillation) or ventricular ectopy (ventricular premature depolarization).
  • Clinically significant and uncontrolled major medical condition(s) that places the subject at an unacceptably high risk for toxicities. These include, but are not limited to: active infections, symptomatic pulmonary disease, inadequate pulmonary function, seizure disorder, psychiatric illness.
  • Current use of more than one antihypertensive medication.
  • For patients receiving antihypertensive medication:systolic blood pressure < 120 mmHg and/or diastolic blood pressure < 70 mmHg at screening.
  • A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as determined by medical history.
  • Major surgical procedure within 4 weeks prior to enrolment.
  • Lactating or pregnant female.
  • Females of childbearing potential and males not using adequate birth control.
  • Current treatment or treatment within 4 weeks of screening with bisphosphonates.
  • Screening serum calcium levels < 2.20 mmol/L [8.8 mg/dL] (after correction for serum albumin
  • History of acute pancreatitis within 12 months prior to screening
  • Known hypoparathyroidism, pseudohypoparathyroidism, or vitamin D deficiency, or clinical evidence of other conditions known to associated with hypocalcemia, including:, hypoalbuminemia, hyperphosphatemia, hypomagnesemia
  • Current treatment or treatment within 4 weeks of screening with drugs known to reduce serum calcium levels, including: bisphosphonates, antiepileptic drugs, cinacalcet, macrolide antibiotics (such as erythromycin, azithromycin), large doses of corticosteroids (>20 mg/day of prednisone or equivalent), or any IV use of corticosteroids. In addition, long-term use (defined as ongoing use for ≥4 weeks) of corticosteroids within 8 weeks of screening is prohibited
  • Any history of a venous thromboembolic event (VTE), including deep vein thrombosis (DVT) or pulmonary embolism (PE)
  • Current treatment or treatment within 7 days of screening with a vitamin K antagonist, such as warfarin. Patients who require anticoagulation due to their central line may receive an alternative agent, such as low molecular weight heparin (LMWH).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01578564

Layout table for location information
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77230-1402
Canada, Ontario
Juravinski Cancer Center
Hamilton, Ontario, Canada, L8V 5C2
London Health Sciences Centre
London, Ontario, Canada, N6A 4L6
Sponsors and Collaborators
Soricimed Biopharma Inc
Layout table for investigator information
Study Director: Toney T Ilenchuk, MS, PhD Soricimed Biopharma Inc
Layout table for additonal information
Responsible Party: Soricimed Biopharma Inc Identifier: NCT01578564    
Other Study ID Numbers: SOR-C13 01
First Posted: April 17, 2012    Key Record Dates
Last Update Posted: June 23, 2016
Last Verified: June 2016
Keywords provided by Soricimed Biopharma Inc:
Ovarian Cancer
TRPV6 Calcium channel
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs